GI SLIDE DECK 2016 2016 Gastrointestinal Cancers Symposium Selected abstracts from:

Supported by Eli Lilly and Company.
Eli Lilly and Company has not influenced the content of this publication
2016 Gastrointestinal Cancers Symposium
21–23 January 2016 | San Francisco, USA
GI SLIDE DECK 2016
Selected abstracts from:

Letter from ESDO
DEAR COLLEAGUES
It is my pleasure to present this ESDO slide set which has been designed to highlight and summarise
key findings in digestive cancers from the major congresses in 2016. This slide set specifically focuses
on the 2016 Gastrointestinal Cancers Symposium and is available in English and Japanese.
The area of clinical research in oncology is a challenging and ever changing environment. Within this
environment, we all value access to scientific data and research which helps to educate and inspire
further advancements in our roles as scientists, clinicians and educators. I hope you find this review of
the latest developments in digestive cancers of benefit to you in your practice. If you would like to
share your thoughts with us we would welcome your comments. Please send any correspondence to
[email protected].
And finally, we are also very grateful to Lilly Oncology for their financial, administerial and logistical
support in the realisation of this activity.
Yours sincerely,
Eric Van Cutsem
Wolff Schmiegel
Phillippe Rougier
Thomas Seufferlein
(ESDO Governing Board)

ESDO Medical Oncology Slide Deck
Editors 2016
BIOMARKERS
Prof Eric Van Cutsem Digestive Oncology, University Hospitals, Leuven, Belgium
Prof Thomas Seufferlein Clinic of Internal Medicine I, University of Ulm, Ulm, Germany
GASTRO-OESOPHAGEAL AND NEUROENDOCRINE TUMOURS
Emeritus Prof Philippe Rougier University Hospital of Nantes, Nantes, France
Prof Côme Lepage University Hospital & INSERM, Dijon, France
PANCREATIC CANCER AND HEPATOBILIARY TUMOURS
Prof Jean-Luc Van Laethem Digestive Oncology, Erasme University Hospital, Brussels, Belgium
Prof Thomas Seufferlein Clinic of Internal Medicine I, University of Ulm, Ulm, Germany
COLORECTAL CANCERS
Prof Eric Van Cutsem Digestive Oncology, University Hospitals, Leuven, Belgium
Prof Wolff Schmiegel Department of Medicine, Ruhr University, Bochum, Germany
Prof Thomas Gruenberger Department of Surgery I, Rudolf Foundation Clinic, Vienna, Austria

Glossary
1L first-line
2L second-line
5-FU 5-fluorouracil
ADC adenocarcinoma
AE adverse event
AFP alpha-fetoprotein
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the curve
bid twice daily
CarPac carboplatin/paclitaxel
CA 19-9 carbohydrate antigen 19-9
CEA carcinoembryonic antigen
CI confidence interval
CNS central nervous system
CR complete response
CRC colorectal cancer
CRT chemoradiotherapy
CT chemotherapy
CyFra21-1 cytokeratin 19 fragment
DCR disease control rate
DFS disease-free survival
ECOG Eastern Cooperative Oncology
Group
ELISA enzyme-linked immunosorbent
assay
EORTC European Organisation for
Research and Treatment of Cancer
ERCC1 excision repair cross-
complementation group 1
(m)FOLFIRI (modified) leucovorin +
5-fluorouracil + irinotecan
(m)FOLFOX (modified) leucovorin +
5-fluorouracil + oxaliplatin
FOLFOXIRI leucovorin + 5-fluorouracil +
oxaliplatin + irinotecan
GC gastric cancer
GEC gastro-oesophageal
adenocarcinoma
GEJ gastro-oesophageal junction
GI gastrointestinal
Gy Gray
HCC hepatocellular carcinoma
HER2 human epidermal growth factor
receptor 2
HGF hepatocyte growth factor
HR hazard ratio
HR-QoL health-related quality of life
CRP High-sensitivity C-reactive protein
IHC immunohistochemistry
IR incidence ratio
ITT intent-to-treat
iv intravenous
177Lu-Dotatate 177Lu-[DOTA0,Tyr3]octreotate
LAR long-acting release
mAb monoclonal antibody
mCRC metastatic colorectal cancer
MET mesenchymal epithelial transition
factor
MMR mismatch repair
n/a not available
NET neuroendocrine tumour
NS non-significant
OR odds ratio
ORR overall/objective response rate
(m)OS (median) overall survival
OxCap oxaliplatin/capecitabine
pCR pathological complete response
PD progressive disease
PDAC pancreatic ductal adenocarcinoma
PD-L1 programmed death-ligand 1
(m)PFS (median) progression-free survival
PK pharmacokinetic
po orally
PR partial response
PS performance status
q(2/3/4/8)w every (2/3/4/8) week(s)
QoL quality of life
RECIST Response Evaluation Criteria In
Solid Tumors
RT radiotherapy
SAE serious adverse event
SCC squamous cell carcinoma
SD stable disease
SEER Surveillance, Epidemiology, and
End Results
SLD sum of longest diameters
SSA somatostatin analogue
SSTR somatostatin receptor
TEAE treatment-emergent adverse event
TIMP1 TIMP metallopeptidase inhibitor 1
TNM Tumour, Node, Metastasis
TTP time to progression
(p)VEGF (plasma) vascular endothelial
growth factor

Contents
•Cancers of the oesophagus and stomach 6
•Cancers of the pancreas, small bowel and hepatobiliary tract 42
–Pancreatic cancer 43
–Hepatocellular carcinoma 53
–Neuroendocrine tumour 61
–General 67
•Cancers of the colon, rectum and anus 73
–Colorectal cancer 74
–Rectal cancer 89
Note: To jump to a section, right click on the number and ‘Open Hyperlink’